1. Pink Sheet

Merck's Ebola Vaccine Will Get US FDA Decision Before March Review Deadline

 
• By Brenda Sandburg

Staffer says agency will make a licensure decision "well ahead" of the March action date; 230,000 have received the vaccine under compassionate use.

Fake ebola vaccine vial with syringe and stethoscope at the background - Image
Merck's Ebola Vaccine Application Is Getting Speedy FDA Review

The US Food and Drug Administration plans to complete review of Merck & Co. Inc.'s Ebola vaccine application before its March 14 user fee date.

Merck began a rolling submission of the biologics license application for the vaccine, V920 (rVSV∆G-ZEBOV-GP), in October 2018

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.